0.14
+2.19%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Xintela
Its shares trade on Nasdaq Stockholm under the ticker XINT.ST. It has been listed since 22 March 2016. In the fiscal year to 31 December 2025, it reported revenue of SEK 2.3m and a net loss of SEK 48.6m. At that date it held total assets of SEK 29.0m and shareholders' equity of −SEK 5.3m.
Xintela AB engages in the development of pharmaceutical products. The company is headquartered in Lund, Skane. The company went IPO on 2016-03-22. In the field of regenerative medicine, the Company focuses on cartilage damage and osteoarthritis, and in the field of brain tumors, its focuses on the development of a treatment for glioblastoma, an aggressive tumor. The firm has developed therapeutic antibodies, which bind to cancer cells. The company has also developed XINMARK, a marker technology which consists of specific proteins, which work as recognition flags on the surface of certain cells. The markers make it possible to identify and select certain types of stem cells which can develop into cartilage cells.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 22 Mar 2016
- Website
- xintela.se ↗
Leadership
Pay as last reported
- Mr. Gregory BatchellerExecutive Chairman of the Board
- Ms. Evy Lundgren-AkerlundChief Executive Officer
- Mr. Gunnar TelhammarChief Financial Officer
- Mr. Sven KiliChief Operating Officer, Chief Medical Officer, Executive Director, since 2014
- Mr. Rickard MosellHead of Business Development
- Mr. Thomas AreschougBusiness Development Manager
- Ms. Caroline EhrencronaDirector Clinical Development and Regulatory Affairs
- Mr. Carl-Magnus HogerkorpProduction Manager
- Ms. Liselotte TheorellDirector Product Development and Quality Management
- Mr. Maarten De ChateauDirector
- Mr. Thomas ElderedDirector
- Mr. Lars HedbysDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Xintela AB develops therapeutic antibodies targeting cancer cells for effective treatment.
- XINMARK marker technology identifies stem cells for cartilage development in regenerative medicine.
- Xintela AB focuses on cartilage damage and glioblastoma treatments in biotechnology sector.
Weaknesses
- Xintela AB's IPO was on 22 March 2016, a relatively recent listing.
- The company's focus on regenerative medicine and brain tumors requires significant R&D investment.
- Xintela AB operates in Lund, Skane, a location with limited biotech infrastructure.
Opportunities
- Xintela AB can expand its regenerative medicine applications for osteoarthritis treatment in Sweden.
- The global market for glioblastoma treatments presents a significant opportunity for Xintela AB.
- Xintela AB's XINMARK technology can be licensed to other biotech firms in the Health Care sector.
Threats
- Xintela AB faces competition from established biotech companies in the Health Care sector.
- Regulatory challenges in developing new pharmaceutical products could delay market entry.
- Xintela AB's reliance on a single therapeutic antibody platform increases business risk.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.